198 related articles for article (PubMed ID: 35687860)
1. The progress of peptide vaccine clinical trials in gynecologic oncology.
Tang M; Cai JH; Diao HY; Guo WM; Yang X; Xing S
Hum Vaccin Immunother; 2022 Nov; 18(5):2062982. PubMed ID: 35687860
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
3. Next-generation peptide vaccines for advanced cancer.
Yamada A; Sasada T; Noguchi M; Itoh K
Cancer Sci; 2013 Jan; 104(1):15-21. PubMed ID: 23107418
[TBL] [Abstract][Full Text] [Related]
4. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
5. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
Kaumaya PT
Future Oncol; 2020 Aug; 16(23):1767-1791. PubMed ID: 32564612
[TBL] [Abstract][Full Text] [Related]
6. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of peptide vaccines in cancer immunotherapy.
Zahedipour F; Jamialahmadi K; Zamani P; Reza Jaafari M
Int Immunopharmacol; 2023 Oct; 123():110721. PubMed ID: 37543011
[TBL] [Abstract][Full Text] [Related]
9. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
[TBL] [Abstract][Full Text] [Related]
10. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
11. Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.
Hos BJ; Tondini E; van Kasteren SI; Ossendorp F
Front Immunol; 2018; 9():884. PubMed ID: 29755468
[TBL] [Abstract][Full Text] [Related]
12. Prospect and progress of personalized peptide vaccinations for advanced cancers.
Sakamoto S; Noguchi M; Yamada A; Itoh K; Sasada T
Expert Opin Biol Ther; 2016; 16(5):689-98. PubMed ID: 26938083
[TBL] [Abstract][Full Text] [Related]
13. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
14. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
15. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.
Rosendahl Huber SK; Camps MG; Jacobi RH; Mouthaan J; van Dijken H; van Beek J; Ossendorp F; de Jonge J
PLoS One; 2015; 10(6):e0127969. PubMed ID: 26046664
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
[TBL] [Abstract][Full Text] [Related]
19. Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.
Ghaffari-Nazari H; Tavakkol-Afshari J; Jaafari MR; Tahaghoghi-Hajghorbani S; Masoumi E; Jalali SA
PLoS One; 2015; 10(11):e0142563. PubMed ID: 26556756
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]